Trial Profile
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid) Alone and in Combination With Epoetin Alfa (Procrit) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Epoetin alfa
- Indications Anaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms ChOPIN
- 05 Oct 2023 Planned End Date changed from 21 Sep 2023 to 21 Sep 2024.
- 11 Oct 2022 Planned End Date changed from 13 May 2026 to 21 Sep 2023.
- 13 Jan 2021 Results published in the Journal of Clinical Oncology